SC
DRUG

Stempoint Capital’s Bright Minds Biosciences DRUG Stock Holding History

Stempoint Capital’s Portfolio DRUG Stock Details DRUG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-97,340
Closed -$7.6M – 95
2025
Q4 		$7.6M Buy
+97,340
New +$6.51M 1.3% 21

Other funds holding DRUG

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Stempoint Capital's DRUG Position: Q1 2026 in Review

Stempoint Capital sold out of Bright Minds Biosciences (DRUG) in Q1 2026, closing a stake of 97,340 shares — an estimated $7.6M sold.

Stempoint Capital first reported a position in DRUG in Q4 2025 and held it in 1 quarter. The position peaked at $7.6M in Q4 2025. 94 funds tracked by Wall St. Rank hold DRUG as of Q1 2026.

  • Stempoint Capital reported no remaining Bright Minds Biosciences position as of Q1 2026 after selling out during the quarter.
  • Stempoint Capital sold 97,340 Bright Minds Biosciences shares in Q1 2026, an estimated $7.6M.
  • Stempoint Capital first reported a position in Bright Minds Biosciences in Q4 2025 and held it in 1 quarter.
  • Stempoint Capital's Bright Minds Biosciences position peaked at $7.6M in Q4 2025.
  • 94 funds tracked by Wall St. Rank held Bright Minds Biosciences as of Q1 2026.

Based on Stempoint Capital's 13F filing for Q1 2026, filed 15 May 2026.